Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021

Summary

According to the recently published report Insulin Like Growth Factor I - Drugs In Development, 2021; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 11 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling.

The report Insulin Like Growth Factor I - Drugs In Development, 2021 outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Metabolic Disorders and Ophthalmology which include indications Neuropathic Pain (Neuralgia), Acute Ischemic Stroke, Age Related Macular Degeneration, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Diabetic Retinopathy, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinsons Disease, Peripheral Nerve Injury, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Retinal Vein Occlusion, Solid Tumor and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)
- The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

TABLE OF CONTENTS

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Overview
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Companies Involved in Therapeutics Development
Boehringer Ingelheim International GmbH
Genervon Biopharmaceuticals LLC
Helixmith Co Ltd
Kriya Therapeutics Inc
Regulaxis SAS
SIFI SpA
Stem Cell Medicine Ltd
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drug Profiles
CIGB-845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTA-832 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-610.27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGC-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xentuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Discontinued Products
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones
Featured News & Press Releases
Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference
Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
Dec 27, 2016: ALS and Alzheimers disease bioinformatics reports confirm GM6s role as regulator of disease-relevant pathways
Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
May 03, 2016: GM604 to Be Granted Orphan Drug Status in Europe
Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results
Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS
Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Boehringer Ingelheim International GmbH, 2021
Pipeline by Genervon Biopharmaceuticals LLC, 2021
Pipeline by Helixmith Co Ltd, 2021
Pipeline by Kriya Therapeutics Inc, 2021
Pipeline by Regulaxis SAS, 2021
Pipeline by SIFI SpA, 2021
Pipeline by Stem Cell Medicine Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drugs in Development, 2021

Insulin Receptor (IR or CD220 or INSR or EC 2.7.10.1) - Drugs in Development, 2021

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drugs in Development, 2021

Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drugs in Development, 2021

FAQs